You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Primary results from a global, phase III trial of adjuvant alectinib vs chemotherapy in patients with completely resected ALK+ NSCLC.
Request medical material
Would you like to receive this poster via email to view later?